Other languages Xenon Pharmaceuticals Inc.

Equities

XENE

CA98420N1050

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-02 pm EDT			5-day change	1st Jan Change
36.56 ^USD	-3.00%		-1.19%	-20.63%

Jun. 12	Transcript : Xenon Pharmaceuticals Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 04:00 PM
Jun. 04	Transcript : Xenon Pharmaceuticals Inc. - Shareholder/Analyst Call

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Xenon Pharmaceuticals Inc. Presents Data from Phase 2 X-Nova Clinical Trial of Azetukalner in Major Depressive Disorder At the American Society of Clinical Psychopharmacology 2024 Annual Meeting	May. 28
Xenon Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09
Xenon Pharmaceuticals Q1 Net Loss Narrows	May. 09
Xenon Pharmaceuticals Inc. Announces Board Resignations	Apr. 19
Xenon Pharmaceuticals Insider Sold Shares Worth $330,290, According to a Recent SEC Filing	Mar. 08
Xenon Pharmaceuticals Insider Sold Shares Worth $601,615, According to a Recent SEC Filing	Mar. 08
Xenon Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29
Xenon Pharmaceuticals Q4 Net Loss Widens	Feb. 29
Xenon Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 29
Xenon Pharmaceuticals Insider Sold Shares Worth $758,983, According to a Recent SEC Filing	Dec. 15
Sector Update: Health Care Stocks Gain Premarket Thursday	Nov. 30
Xenon Pharmaceuticals Prices $300 Million Public Offering of Common Stock, Pre-Funded Warrants	Nov. 30
Xenon Pharmaceuticals Launches $225 Million Public Offering	Nov. 29
Xenon Pharmaceuticals Says Trial of Depression Drug Failed to Meet Primary Endpoint	Nov. 27
Canada's Xenon Pharma's depression drug fails to meet main goal in study	Nov. 27
Xenon Pharmaceuticals' depression drug fails to meet main goal in study	Nov. 27
Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-Of-Concept X-Nova Clinical Trial of Xen1101 in Major Depressive Disorder	Nov. 27
Sector Update: Health Care Stocks Rising Late Afternoon	Nov. 10
Sector Update: Health Care Stocks Rise Friday Afternoon	Nov. 10
Neurocrine Reports Two Mid-Stage Trial Misses; Shares Fall	Nov. 10

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Xenon Pharmaceuticals Inc.

Equities

XENE

CA98420N1050

Other languages

Filters